Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Por um escritor misterioso
Descrição
Ongoing immunotherapy trials in neoadjuvant and adjuvant settings and
VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
Neoadjuvant or adjuvant immunotherapy in melanoma stage iii
Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA
Frontiers Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer
Timing is Everything: Neoadjuvant Versus Adjuvant Immunotherapy in Patients with Resectable Metastatic Melanoma
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial - The Lancet
de
por adulto (o preço varia de acordo com o tamanho do grupo)
